BioSpace News Archive

Miri today announces its lineup of experts infusing the knowledge provided to users.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB).

Soleno Therapeutics, Inc. today announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS).

Syneos Health® has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients.

Inozyme Pharma, Inc. today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

Avantor, Inc. today announced that Benoit Gourdier will join the company as EVP, Biopharma Production on October 2, 2023.

AltruBio Inc. announced clearance of its Investigational New Drug application from the U.S. Food and Drug Administration to initiate a Phase 2 clinical study of the company’s subcutaneously administered immune checkpoint enhancer, ALTB-268 in ulcerative colitis.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed cohort dosing of healthy male and female subjects in its Phase I/II clinical trial evaluating its lead anti-infective candidate, RECCE® 327 (R327), at faster infusion rates.

Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced two poster presentations at the 30th Annual European Society of Gene & Cell Therapy (ESGCT) Conference, to be held in Brussels, Belgium from October 24 – 27, 2023.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces its participation in the American Society for Radiation Oncology (ASTRO) Annual Meeting to be held in San Diego from October 1-4.